Leukemia, Myeloid, Chronic Clinical Trial
Official title:
Safety Assessment of a Peptide Vaccine Derived From Bcr-abl Along With Cytokine Genes in CML Patients Undergoing Imatinib Treatment
Verified date | May 2012 |
Source | Tehran University of Medical Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | Iran: Ministry of Health |
Study type | Interventional |
The primary purpose of this study is to evaluate the safety of a peptide-gene vaccine
against CML in patients under Imatinib treatment.
We will also perform some laboratory tests suggesting biological response.
Status | Completed |
Enrollment | 12 |
Est. completion date | November 2011 |
Est. primary completion date | December 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Patients with Philadelphia chromosome positive CML who are: 1. of subtype b3a2 2. In first complete hematologic response; 3. have received imatinib for > 12 months of which the last 3 months were at a stable dose of at least 400 mg/day; 4. have PCR detectable BCR-ABL transcript by qRT-PCR, and 5. with persistent disease, as defined by <1 log reduction in peripheral blood or bone marrow BCR-ABL transcripts levels compared with a standardized baseline. - Greater than or equal to 18 years in age - No known infection with human immunodeficiency virus - Physician and patient willingness to maintain the baseline dose of imatinib throughout the study period - Written informed consent obtained from the patient Exclusion Criteria: - Female patients who are pregnant or breast feeding or adults of childbearing age who are not using adequate birth control. - Current use of systemic immunosuppressive medications - ALT or AST >3X Upper limit Normal - Prior allogeneic stem cell transplantation - Other experimental therapy within the past two months - Prior participation in vaccine studies within the past six months - Oxygen saturation of less than 95% at room air - History of recent acute myocardial infarction, unstable angina, or pulmonary decompensation requiring hospitalization within the past 3 months. - Concurrent and or uncontrolled psychiatric or medical condition which may interfere with the study completion. |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Iran, Islamic Republic of | Hematology-Oncology & SCT Research Center | Tehran |
Lead Sponsor | Collaborator |
---|---|
Tehran University of Medical Sciences |
Iran, Islamic Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess safety of bcr-abl peptide vaccination in Ph+ or MRD CML patients | At enroll in study and 3 months after intervention | Yes | |
Secondary | To measure the development of a molecular response to vaccination as measured by 1 log decrease in qRT-PCR BCR-ABL levels for at least 3 months; To measure the development of immune response following vaccination | At enroll in study and 3 months after intervention | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00393380 -
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
|
Phase 2 | |
Completed |
NCT00186342 -
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies
|
N/A | |
Completed |
NCT00759837 -
Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects
|
Phase 1 | |
Completed |
NCT00538109 -
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
|
N/A | |
Completed |
NCT00040105 -
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
|
Phase 1 | |
Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A | |
Recruiting |
NCT01015742 -
Unrelated Double Umbilical Cord Blood Units Transplantation
|
Phase 2/Phase 3 | |
Completed |
NCT00406393 -
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
|
Phase 3 | |
Completed |
NCT00246662 -
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT00264160 -
Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy
|
Phase 2/Phase 3 | |
Terminated |
NCT00306332 -
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation
|
Phase 3 | |
Terminated |
NCT00058747 -
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™
|
Phase 2 | |
Active, not recruiting |
NCT00538447 -
Prospective Database for Chronic Myelogenous Leukemia
|
N/A | |
Terminated |
NCT01050946 -
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
|
Phase 2 | |
Completed |
NCT00034684 -
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04260022 -
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
|
Phase 1 | |
Terminated |
NCT00167180 -
Post Transplant Donor Lymphocyte Infusion
|
Phase 2 | |
Terminated |
NCT00449761 -
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
|
Phase 2 | |
Completed |
NCT00298987 -
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
|
Phase 2 | |
Completed |
NCT00763763 -
Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive
|
Phase 2 |